Longitudinal Profiles of Anti-Platelet Factor 4 Antibodies in Thai People Who Received ChAdOx1 nCoV-19 Vaccination.
Asian
COVID-19 vaccine
VITT
vaccine-induced thrombocytopenia and thrombosis
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
17 Mar 2023
17 Mar 2023
Historique:
received:
31
01
2023
revised:
04
03
2023
accepted:
16
03
2023
medline:
31
3
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
Anti-platelet factor 4 (anti-PF4) antibodies were identified as pathogenic antibodies for vaccine-induced immune thrombocytopenia and thrombosis (VITT) in subjects receiving ChAdOx1 nCoV-19 vaccinations. We performed a prospective cohort study to determine the prevalence of anti-PF4 and the effect of the ChAdOx1 nCoV-19 vaccine on anti-PF4 in healthy Thai subjects. Anti-PF4 antibodies were measured before and four weeks after receiving the first vaccination. Participants with detectable antibodies were scheduled for repeat anti-PF4 analysis at 12 weeks after the second vaccination. Of 396 participants, ten participants (2.53%; 95% confidence interval [CI], 1.22-4.59) were positive for anti-PF4 before receiving vaccinations. Twelve people (3.03%; 95% CI, 1.58-5.23) had detectable anti-PF4 after the first vaccination. There was no difference in the optical density (OD) values of anti-PF4 antibodies when comparisons were made between pre-vaccination and four weeks after the first vaccination (
Identifiants
pubmed: 36992276
pii: vaccines11030692
doi: 10.3390/vaccines11030692
pmc: PMC10059030
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Faculty of Medicine Research Fund, Chiang Mai University, Thailand.
ID : 133-2564
Références
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399
Semin Hematol. 2022 Apr;59(2):97-107
pubmed: 35512907
Res Pract Thromb Haemost. 2022 Jan 15;6(1):e12644
pubmed: 35071968
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Res Pract Thromb Haemost. 2021 Sep 18;5(6):e12580
pubmed: 34568726
Vaccines (Basel). 2022 Jan 30;10(2):
pubmed: 35214675
Front Immunol. 2021 Nov 04;12:775267
pubmed: 34804066
Lancet Reg Health Eur. 2022 Jan;12:100270
pubmed: 34901912
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
J Thromb Haemost. 2021 Aug;19(8):2007-2013
pubmed: 33973336
BMJ. 2022 Apr 27;377:e069317
pubmed: 35477670
Trop Med Infect Dis. 2023 Jan 31;8(2):
pubmed: 36828511
Res Pract Thromb Haemost. 2021 Oct 11;5(7):e12600
pubmed: 34667921
Medicine (Baltimore). 2022 Sep 9;101(36):e30281
pubmed: 36086694
N Engl J Med. 2021 Oct 28;385(18):1680-1689
pubmed: 34379914
Blood. 2021 Dec 2;138(22):2256-2268
pubmed: 34587242
Vaccines (Basel). 2021 Sep 28;9(10):
pubmed: 34696204
J Thromb Haemost. 2021 Jul;19(7):1813-1818
pubmed: 33909350
Med J Armed Forces India. 2021 Jul;77:S283-S288
pubmed: 34334895
Postgrad Med J. 2022 May 1;98(1159):389-394
pubmed: 37066438
Semin Hematol. 2022 Apr;59(2):72-75
pubmed: 35512903
Res Pract Thromb Haemost. 2021 Nov 21;5(8):e12625
pubmed: 34849450
Intern Med J. 2007 Sep;37(9):607-13
pubmed: 17543005
J Scleroderma Relat Disord. 2021 Jun;6(2):178-186
pubmed: 35386738
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
Lancet. 2022 Oct 8;400(10359):1224-1280
pubmed: 36115368
Blood. 2021 Jul 29;138(4):299-303
pubmed: 33988688
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
J Thromb Haemost. 2022 Jan;20(1):149-156
pubmed: 34693641
Am J Clin Pathol. 2010 Nov;134(5):774-80
pubmed: 20959660